Next Article in Journal
Future Prospects for the Development of Cost-Effective Adenovirus Vaccines
Next Article in Special Issue
A Long-Term Treatment with Arachidonyl-2′-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy
Previous Article in Journal
Cytosolic BNIP3 Dimer Interacts with Mitochondrial BAX Forming Heterodimers in the Mitochondrial Outer Membrane under Basal Conditions
Article

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease

1
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Investigación en Neuroquímica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
2
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain
3
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28040 Madrid, Spain
4
Unidad de Cartografía Cerebral, Instituto Pluridisciplinar, Universidad Complutense, 28040 Madrid, Spain
5
Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain
6
Departamento de Fisiología, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Both authors shared the senior authorship of this study.
Academic Editors: Daniela Parolaro and Tiziana Rubino
Int. J. Mol. Sci. 2017, 18(4), 684; https://doi.org/10.3390/ijms18040684
Received: 22 February 2017 / Revised: 15 March 2017 / Accepted: 17 March 2017 / Published: 23 March 2017
(This article belongs to the Special Issue Cannabinoid Signaling in Nervous System)
Several cannabinoids afforded neuroprotection in experimental models of Huntington’s disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either ∆9-tetrahydrocannabinol (∆9-THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex®, is beneficial in R6/2 mice (a transgenic model of HD), as it was previously shown to have positive effects in neurotoxin-based models of HD. We recorded the progression of neurological deficits and the extent of striatal deterioration, using behavioral, in vivo imaging, and biochemical methods in R6/2 mice and their corresponding wild-type mice. The mice were daily treated, starting at 4 weeks after birth, with a Sativex-like combination of phytocannabinoids (equivalent to 3 mg/kg weight of pure CBD + ∆9-THC) or vehicle. R6/2 mice exhibited the characteristic deterioration in rotarod performance that initiated at 6 weeks and progressed up to 10 weeks, and elevated clasping behavior reflecting dystonia. Treatment with the Sativex-like combination of phytocannabinoids did not recover rotarod performance, but markedly attenuated clasping behavior. The in vivo positron emission tomography (PET) analysis of R6/2 animals at 10 weeks revealed a reduced metabolic activity in the basal ganglia, which was partially attenuated by treatment with the Sativex-like combination of phytocannabinoids. Proton nuclear magnetic resonance spectroscopy (H+-MRS) analysis of the ex vivo striatum of R6/2 mice at 12 weeks revealed changes in various prognostic markers reflecting events typically found in HD patients and animal models, such as energy failure, mitochondrial dysfunction, and excitotoxicity. Some of these changes (taurine/creatine, taurine/N-acetylaspartate, and N-acetylaspartate/choline ratios) were completely reversed by treatment with the Sativex-like combination of phytocannabinoids. A Sativex-like combination of phytocannabinoids administered to R6/2 mice at the onset of motor symptoms produced certain benefits on the progression of striatal deterioration in these mice, which supports the interest of this cannabinoid-based medicine for the treatment of disease progression in HD patients. View Full-Text
Keywords: phytocannabinoids; cannabidiol; Δ9-tetrahydrocannabinol; Huntington’s disease; R6/2 mice; basal ganglia; neuroprotection phytocannabinoids; cannabidiol; Δ9-tetrahydrocannabinol; Huntington’s disease; R6/2 mice; basal ganglia; neuroprotection
Show Figures

Graphical abstract

MDPI and ACS Style

Valdeolivas, S.; Sagredo, O.; Delgado, M.; Pozo, M.A.; Fernández-Ruiz, J. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease. Int. J. Mol. Sci. 2017, 18, 684. https://doi.org/10.3390/ijms18040684

AMA Style

Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease. International Journal of Molecular Sciences. 2017; 18(4):684. https://doi.org/10.3390/ijms18040684

Chicago/Turabian Style

Valdeolivas, Sara, Onintza Sagredo, Mercedes Delgado, Miguel A. Pozo, and Javier Fernández-Ruiz. 2017. "Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease" International Journal of Molecular Sciences 18, no. 4: 684. https://doi.org/10.3390/ijms18040684

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop